Jefferies Financial Group Inc. Sells 284,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Jefferies Financial Group Inc. reduced its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 90.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,048 shares of the company's stock after selling 284,000 shares during the quarter. Jefferies Financial Group Inc.'s holdings in 10x Genomics were worth $446,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. FMR LLC lifted its holdings in 10x Genomics by 0.6% in the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock valued at $193,206,000 after acquiring an additional 86,455 shares during the period. ARK Investment Management LLC boosted its holdings in 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock worth $171,517,000 after buying an additional 1,193,712 shares in the last quarter. RA Capital Management L.P. acquired a new position in 10x Genomics during the fourth quarter worth about $47,092,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in 10x Genomics by 10.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock worth $30,394,000 after buying an additional 193,588 shares during the period. Finally, Voloridge Investment Management LLC increased its holdings in 10x Genomics by 12.1% in the fourth quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock valued at $22,774,000 after buying an additional 171,161 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Stock Up 2.5%

Shares of 10x Genomics stock traded up $0.23 during trading on Wednesday, hitting $9.34. The stock had a trading volume of 3,489,269 shares, compared to its average volume of 2,458,979. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $24.76. The stock has a 50 day simple moving average of $8.46 and a 200 day simple moving average of $11.74. The company has a market capitalization of $1.15 billion, a PE ratio of -6.14 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The company had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. During the same quarter in the prior year, the company earned ($0.50) EPS. The firm's quarterly revenue was down 2.3% on a year-over-year basis. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, May 24th. Stephens reissued an "overweight" rating and issued a $14.00 price objective on shares of 10x Genomics in a research note on Thursday, May 15th. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Leerink Partnrs downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $15.81.

Insider Transactions at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,485 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the transaction, the insider now owns 448,374 shares of the company's stock, valued at approximately $3,721,504.20. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,343 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $77,546.90. Following the transaction, the chief executive officer now owns 1,083,625 shares in the company, valued at approximately $8,994,087.50. The trade was a 0.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,872 shares of company stock valued at $173,238 in the last three months. Corporate insiders own 9.39% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.